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PIN5
RELATIONSHIP BETWEEN PRESCRIPTION USE
AND ANTIMICROBIAL RESISTANCE IN THE
COMMUNITY:AN EXPLORATION
Sahm D1, Master R1, Roberts C2, McLaughlin T3, Hansen J1
1Focus Technologies, Inc, Herndon,VA, USA; 2NDCHealth,
Yardley, PA, USA; 3NDCHealth, Phoenix, AZ, USA
OBJECTIVE: Numerous analyses have attempted to
quantify the relationship between antibiotic use and resis-
tance patterns. This represents one of the ﬁrst systematic
explorations of antibiotic use and resistance using large
population datasets across multiple regions of the
country. The objective was to explore the relationship
between antibiotic use in the community and antibiotic
resistance across multiple metropolitan statistical areas
(MSAs). METHODS: Prescriptions for ﬂuoroquinolone,
beta-lactam, and macrolide antibiotics were collected on
a monthly basis from retail pharmacy data in 20 MSAs
during July 2000–June 2002. Antimicrobial susceptibility
tests from community sites in corresponding MSAs were
collected from 07/01–06/02 to calculate percent resis-
tance of P aeruginosa, E coli, and S pneumonia, for sites
where at least 20 such tests were performed per year. The
correlation between percent resistance of the organisms
and the number of prescriptions per population within
the MSA was calculated. RESULTS: Mean prescription
use per person in an MSA during July 2000–June 2002
was 0.660 for beta-lactams, 0.326 for macrolides and
0.199 for ﬂuoroquinolones. During July 2001–June
2002, approximately 6.9% of E coli isolates and 31.3%
of P aeruginosa isolates were resistant to ﬂuoro-
quinolones. S pneumonia resistance to beta-lactams,
macrolides, and ﬂuoroquinolones was 19.3%, 31.9%,
and 0.5%, respectively. Correlation between resistance
and ﬂuoroquinolone use was 0.396 (N = 19, p = 0.093)
for E coli and 0.517 (N = 19, p = 0.024) for P aerugi-
nosa. The correlation between antibiotic use / % resis-
tance for S pneumoniae was 0.158 for beta-lactams (N =
9, p = 0.684), 0.650 for macrolides (N = 10, p = 0.042),
and -0.048 for quinolones (N = 8, p = 0.227). CON-
CLUSIONS: There was a moderate correlation between
the level of antibiotic use within the community and the
corresponding level of antibiotic resistance. Poorer corre-
lation was observed with S pneumoniae resistance to
beta-lactams and ﬂuoroquinolones, the latter largely due
to a lack of resistance detected during the time period.
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IMPACT OF CHANGES IN REIMBURSEMENT
POLICY ON ANTIBIOTIC RESISTANCE
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Hospital,Toronto, ON, Canada; 3University of Toronto,
Toronto, ON, Canada; 4Bayer Inc,Toronto, ON, Canada
OBJECTIVES: In February 2001, the Ontario Drug
Beneﬁt (ODB) Formulary was changed so that most ﬂu-
oroquinolone (FQ) antibiotics would be reimbursed as
Limited Use (LU) or subject to further LU restrictions in
response to concerns about increasing rates of resistance
to the FQs. This study analyzed the impact of the LU
policy on antibiotic resistance, particularly in community
acquired pathogens. METHODS: Ontario data from the
Canadian Bacterial Surveillance Network aggregated by
month between Jan 1, 1998 and June 30, 2002 examines
various drug/pathogen combinations for resistance. Strep-
tococcus pneumoniae (4765 isolates) was tested for sus-
ceptibility to various drugs while group A Streptococcus
(1210 isolates), and Haemophilus inﬂuenzae (761 iso-
lates) were tested for susceptibility to a single drug. The
effect of the LU policy on the level and rate of change 
of antibiotic resistance was estimated using time series
analysis with ARIMA models, where indicated by auto-
correlation, or Poisson regression models where autocor-
relation was not present. RESULTS: Resistance rates for
S. pneumoniae were in the range of 10–12% for peni-
cillin, erythromycin and trimethoprim sulfamethoxazole
(TMP/SMX) and less than 3% for amoxicillin and all
three FQs tested. Resistance for group A Streptococcus to
erythromycin was about 7% and for H. ﬂu to ampicillin
was about 27%. There was a steady increase in resistance
rates of S. pneumoniae to amoxicillin and levoﬂoxacin
throughout the study period. There was, however, no
indication of any decrease in resistance rates associated
with the LU policy. CONCLUSIONS: Although no direct
cause and effect can be proven with these observational
data, there is no evidence that the LU policy to restrict
FQs decreased resistance in any of the drug/pathogen
combinations tested during the 17 month post-policy
period.
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IMPACT OF THE GRIER CONSENT DECREE ON
ANTIBIOTIC COSTS FOR TENNCARE’S
MANAGED MEDICAID PROGRAM
Bramley TJ1, Regan T1, Sullivan L2, Eaddy M1
1Applied Health Outcomes,Tampa, FL, USA; 2State of
Tennessee, Nashville,TN, USA
OBJECTIVE: Under the Grier Consent Decree (GCD),
when a provider prescribes a non-formulary medication
for a TennCare enrollee, the enrollee is entitled to a 14-
day supply of prescribed medication. The purpose of this
research was to evaluate the effect the GCD had on
antibiotic costs. METHODS: Pharmacy data from the
TennCare administrative database was used in evaluating
the impact of the GDC. The “Grier-effect” was investi-
gated using two different models. An economic forecast-
ing model was constructed using data from the 20 months
(March 1999 to October 2000) preceding the implemen-
tation of the GCD. The model projected per member 
per month (PMPM) antibiotic expenditures in the nine
months following the GCD (November 2000 to July
2001). The difference between actual expenditures and
projected expenditures provided an estimate of the
“Grier-effect”. Per member per month (PMPM) antibiotic
